On the fly News and insights, exclusive to thefly.com



$0.88 /

-3.275 (-78.82%)


H.C. Wainwright downgrades Tocagen with no target after 'major setback'

H.C. Wainwright analyst Swayampakula Ramakanth downgraded Tocagen to Neutral from Buy without a price target after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival. Furthermore, all secondary endpoints, including durable response rate, durable clinical benefit rate, duration of response, and overall survival at 12 months, showed no meaningful difference between the different treatment arms of the study, Ramakanth tells investors in a research note. The analyst views the results as a "major setback" for Tocagen. He now sees "increasing uncertainty" regarding the company's other programs and is not comfortable giving the stock a price target due to the "limited visibility" of Tocagen's pipeline development strategy going forward. The stock in morning trading is down 79%, or $3.32, to 86c.

  • 12


TOCA Tocagen
$0.88 /

-3.275 (-78.82%)

09/12/19 H.C. Wainwright
Tocagen downgraded to Neutral from Buy at H.C. Wainwright
09/12/19 Cantor Fitzgerald
Tocagen downgraded to Neutral from Overweight at Cantor Fitzgerald
09/12/19 Baird
Tocagen downgraded to Neutral from Outperform at Baird
05/30/19 Citi
Tocagen assumed with a Buy at Citi

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.